7
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-7,bridge-core-3.1.4,qode-page-transition-enabled,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,qode-child-theme-ver-1.0.0,qode-theme-ver-30.3,qode-theme-bridge,disabled_footer_top,qode-wpml-enabled,wpb-js-composer js-comp-ver-7.6,vc_responsive

People with Down syndrome often get Alzheimer’s disease (a type of dementia) when they get older. Dementia is a disease that causes memory loss and other thinking problems. Dementia due to Alzheimer’s occurs when a protein called amyloid builds up in the brain.

About ABATE Study

The ABATE Study is testing a vaccine for Alzheimer’s.

We want to see if the vaccine is safe. We also want to see if it slows the progression of Alzheimer’s disease in people with Down syndrome.

About 80 people with Down syndrome will take part in the ABATE Study.

 

The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium – Down Syndrome – ACTC-DS. 

ACTC-DS Logo_400x130

Who is eligible for the ABATE Study?

You may be able to join this study if you:

Have Down Syndrome

Are between 35 and 50 years old

Have a study partner

Your study partner is someone who could support you during your participation. For example, they could be a family member or any relative close to you, or a carer.

If you are interested, please contact your nearest research center to learn more about the ABATE Study and check your eligibility.

What is the study treatment?

The study treatment, ACI-24.060, is a new vaccine which is not yet on the market. It may help to remove amyloid in the brain. This could slow down memory loss and thinking problems.
In the ABATE Study, you will receive either the vaccine or an inactive vaccine (also called placebo). This is so we can see how the vaccine affects your body. Neither you nor the study team will know which vaccine you are getting.

 

You will get the vaccine or inactive vaccine, as well as any tests and visits for the study, at no cost.

What happens in the ABATE Study?

The study lasts for about 2 years and is split into 3 parts:

  • Screening period

    The study team will do tests to see if you meet the criteria to join the study. If you can join, you and your study partner will sign consent forms before you begin.

  • Treatment period

    You will get either the vaccine or inactive vaccine 6 times. You will also have visits at the study clinic and phone calls so the study team can check your health and check how the vaccine is working in your body.

  • Follow-up period

    You won’t get the vaccine or inactive vaccine anymore. You will have some visits to check your health and see how the vaccine is working in your body.

Study site location & contact

ABATE is recruiting participants at research centers across the United States, UK and Spain.
To learn more, please contact the nearest study team.

USA

Coming Soon

Vanderbilt University Medical Center

Center for Cognitive medecine

Amy Boegel

615-875-0955

amy.r.boegel@vumc.org

1601 23rd Avenue South,
37212, Nashville, Tennessee

Now enrolling

University of Kansas Medical Center

Alzheimer’s Disease Research Center

Keri Cox

913-945-7037

kcox11@kumc.edu

4350 Shawnee Mission Parkway, Suite 1200, 66205, Fairway, Kansas

Now enrolling

Barrow Neurological Institute

Alzheimer’s Disease and Memory Disorders Division

Jalisa Santiago

800-392-2222

jalisa.santiago@commonspirit.org

240 W Thomas Rd,
Suite 301,
85013, Phoenix, Arizona

Coming Soon

Washington University in St. Louis

Britany Nelson

314-747-8425

bmnelson@wustl.edu

660 S. Euclid, CB 8111,
63110, St-Louis, Missouri

Now enrolling

Massachusetts General Hospital (MGH)

Mikayla Shaffer

617-643-8912

researchdownsyndrome@mgh.harvard.edu

185 Cambridge Street,
Suite 2.222,
02114, Boston, Massachusetts

Now enrolling

Indiana University / IU Health

Neuroscience Center

Kate Phillips

317-278-3260

philkate@iu.edu

355 W 16th Street, 46202, Indianapolis, Indiana

Now enrolling

UT Health San Antonio

Biggs Institute for Alzheimer’s and Neurodegenerative Diseases

Floyd Jones

210-450-3158

jonesfa@uthscsa.edu

MC 8070, 7703 Floyd Curl Dr.
78229, San Antonio, Texas

UK

Now enrolling

King’s College London

Institute of Psychiatry, Psychology and Neuroscience

Charlie Mizon

07743754760

Charles.mizon@kcl.ac.uk

16 De Crespigny Park, London, SE5 8AF

Now enrolling

Windsor Research Unit

Fulbourn Hospital

Madelaine Smith & Blessing Ushie

07837067964

madelaine.smith9@cpft.nhs.uk or blessing.ushie@cpft.nhs.uk

Fulbourn Hospital, Cambridge,CB21 5EF

Now enrolling

NIHR Oxford Health Clinical Research Facility

Warneford Hospital

Abigail Stewart & Rachel Delahay

01865902135

Abigail1.Stewart@oxfordhealth.nhs.uk Rachel.Delahay@oxfordhealth.nhs.uk oxfordhealth.crf@nhs.net

Warneford Lane, Oxford, OX3 7JX

Spain

Now enrolling

Hospital de la Santa Creu I Sant Pau

Juan Fortea & Isabel Barroeta

jfortea@santpau.cat & ibarroeta@santpau.cat

C/ Mas casanovas, 90. Bloc A, planta -2 (AGDAC), 08025, Barcelona

Now enrolling

Hospital Universitario de la Princesa

Fernando Moldenhauer Diaz

915 202 222

fernando.moldenhauer@salud.madrid.org

Calle de Diego de León, 62,28006, Madrid

Now enrolling

Hospital Universitario Marqués de Valdecilla

Unidad de Deterioro Cognitivo, Servicio de Neurología

Eloy Rodriguez & Andrea Corrales

942 202 520 extensión73650

Deterioro.cognitivo.humv@scsalud.es

Av. de Valdecilla, 25,39008, Santander

Now enrolling

Hospital Universitario Virgen De Las Nieves

Consultas Externas

Elizabeth Garcia Penalver

958 895 426

eligarpe28@hotmail.com

Calle Dr. Azpitarte 4, ( 5ª planta), 18012, Granada